title: Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
abstract: The consistent positive correlation between triglyceride and plasminogen activator inhibitor-1 (PAI-1) levels in plasma and the fact that very low density lipoprotein (VLDL) induces secretion of PAI-1 from cultured human umbilical vein endothelial cells (HUVECs) and human hepatoblastoma cells have raised the question of whether fibrate treatment, the main effect of which is a profound lowering of plasma concentrations of VLDL, might improve fibrinolytic function by reducing the plasma levels of PAI-1. However, the findings of controlled clinical trials using various fibrate compounds have been discrepant. ECs express PAI-1 under normal conditions in humans. We therefore examined the effects of several fibrate compounds on PAI-1 expression and secretion by cultured HUVECs and the HUVEC-derived cell line EA.hy926. All fibrate compounds examined had significant effects on PAI-1 gene transcription in the EA.hy926 cells. Low concentrations of clofibric acid and bezafibrate increased PAI-1 transcription and secretion, whereas Wy-14643 increased PAI-1 synthesis in a dose-dependent way. In contrast, both fenofibric acid and gemfibrozil markedly decreased PAI-1 transcription and secretion from HUVECs and EA.hy926 cells. Thus, stimulation of the transcriptional activity of the PAI-1 gene by some fibrates is linked to increased secretion of PAI-1 protein by the cells, whereas the opposite effects occur with other fibrate compounds. Whether the different effects on PAI-1 transcription and secretion by ECs in vitro also reflect differences in treatment effects on the regulation of plasma PAI-1 activity in vivo will have to be determined in larger-scale, controlled clinical trials.
authors.affiliation: Atherosclerosis Research Unit, King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden. lennart@instmed.ks.se
authors.forename: L
authors.initials: L
authors.lastname: Nilsson
authors.forename: T
authors.initials: T
authors.lastname: Takemura
authors.forename: P
authors.initials: P
authors.lastname: Eriksson
authors.forename: A
authors.initials: A
authors.lastname: Hamsten
mesh_terms: D001629:Bezafibrate / Q000494:pharmacology; D002478:Cells, Cultured; D002995:Clofibric Acid / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D011345:Fenofibrate / Q000031:analogs & derivatives / Q000494:pharmacology; D015248:Gemfibrozil / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis* / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D000077154:Rosiglitazone; D013844:Thiazoles / Q000494:pharmacology; D045162:Thiazolidinediones; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D000960:Hypolipidemic Agents; D017395:Plasminogen Activator Inhibitor 1; D011743:Pyrimidines; D012333:RNA, Messenger; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002995:Clofibric Acid; C006253:pirinixic acid; C006012:fenofibric acid; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate